Pediatrix Medical Group (NYSE:MD) and Amarantus Bioscience (OTCMKTS:AMBS) are both prominent players in the medical sector, each focusing on distinct areas of healthcare. A comparison of their stock performance reveals significant differences in profitability, risk levels, and institutional support, which may influence investor decisions.
Risk and Volatility Assessment
Pediatrix Medical Group exhibits a beta of 0.73, indicating that its stock is approximately 27% less volatile than the S&P 500 index. This suggests a more stable investment environment for those seeking lower risk. In contrast, Amarantus Bioscience has a beta of 1.59, meaning its stock is 59% more volatile. This higher volatility can be appealing to investors who are comfortable with risk in pursuit of potentially greater returns.
Institutional and Insider Ownership
Ownership structures provide insight into investor confidence. A substantial **97.7%** of Pediatrix Medical Group’s shares are held by institutional investors, reflecting strong confidence from major funds and investment firms. Only **0.9%** of its shares are owned by company insiders, suggesting limited internal investment. On the other hand, Amarantus Bioscience has **10.3%** of its shares held by insiders, indicating some level of insider confidence but still falling short of Pediatrix’s institutional backing.
Analysts often view high institutional ownership as a positive indicator, suggesting that large investors believe in a company’s long-term performance potential.
Financial Performance and Profitability
When examining financial results, Pediatrix Medical Group outperforms Amarantus Bioscience in several key metrics. Although Amarantus generates higher earnings, it reported lower revenue figures compared to Pediatrix. This discrepancy highlights the challenges Amarantus faces in achieving consistent income streams, despite its promising developments in biopharmaceuticals.
Profitability comparisons show that Pediatrix Medical Group leads with more favorable net margins, return on equity, and return on assets. This performance positions Pediatrix as a more attractive option for investors prioritizing profitability.
Company Profiles
Pediatrix Medical Group, Inc., founded in **1979** and based in **Sunrise, Florida**, provides a wide range of pediatric healthcare services. Its offerings include neonatal care, maternal-fetal medicine, and pediatric cardiology. The company was previously known as MEDNAX, Inc. until its rebranding in **July 2022**.
Amarantus BioScience Holdings, Inc. focuses on developing diagnostic and therapeutic products, particularly in neurology and regenerative medicine. Founded in **2008** and headquartered in **New York**, Amarantus is working on promising projects like the LymPro test for Alzheimer’s disease and other treatments targeting Parkinson’s and cancer. The company changed its name from Amarantus Bioscience, Inc. in **April 2013** to reflect its expanded focus.
In summary, while both Pediatrix Medical Group and Amarantus Bioscience operate within the healthcare sector, they cater to different needs and markets. Pediatrix Medical Group stands out for its stability and institutional backing, making it a compelling option for conservative investors. Conversely, Amarantus, with its focus on innovative biopharmaceuticals, may appeal to those willing to embrace higher risk for potentially greater rewards. As investors weigh their options, understanding these distinctions is crucial for making informed financial decisions.
